JP2016501066A - 血管塞栓システム - Google Patents
血管塞栓システム Download PDFInfo
- Publication number
- JP2016501066A JP2016501066A JP2015542401A JP2015542401A JP2016501066A JP 2016501066 A JP2016501066 A JP 2016501066A JP 2015542401 A JP2015542401 A JP 2015542401A JP 2015542401 A JP2015542401 A JP 2015542401A JP 2016501066 A JP2016501066 A JP 2016501066A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- peptide
- biological vessel
- biological
- catheter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000010102 embolization Effects 0.000 title description 33
- 230000002792 vascular Effects 0.000 title description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 282
- 238000000034 method Methods 0.000 claims abstract description 107
- 150000001413 amino acids Chemical class 0.000 claims abstract description 48
- 230000000903 blocking effect Effects 0.000 claims abstract description 14
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 14
- 101800002011 Amphipathic peptide Proteins 0.000 claims abstract description 6
- 239000000017 hydrogel Substances 0.000 claims description 86
- 239000002872 contrast media Substances 0.000 claims description 21
- 230000004962 physiological condition Effects 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 238000003384 imaging method Methods 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000017531 blood circulation Effects 0.000 claims description 9
- 210000003743 erythrocyte Anatomy 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000017074 necrotic cell death Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 239000011148 porous material Substances 0.000 claims description 7
- 206010062325 Congenital arterial malformation Diseases 0.000 claims description 6
- 239000002121 nanofiber Substances 0.000 claims description 6
- 208000003278 patent ductus arteriosus Diseases 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000036244 malformation Effects 0.000 claims description 5
- 208000022211 Arteriovenous Malformations Diseases 0.000 claims description 4
- 208000027205 Congenital disease Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000005744 arteriovenous malformation Effects 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims description 3
- 208000000616 Hemoptysis Diseases 0.000 claims description 3
- 201000008450 Intracranial aneurysm Diseases 0.000 claims description 3
- 208000018525 Postpartum Hemorrhage Diseases 0.000 claims description 3
- 206010071229 Procedural haemorrhage Diseases 0.000 claims description 3
- 208000001780 epistaxis Diseases 0.000 claims description 3
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims description 3
- 208000011309 nasal bleeding Diseases 0.000 claims description 3
- 238000002601 radiography Methods 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 2
- 201000010260 leiomyoma Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000007865 diluting Methods 0.000 claims 1
- 150000001768 cations Chemical class 0.000 abstract description 11
- 239000007864 aqueous solution Substances 0.000 abstract description 8
- 239000000243 solution Substances 0.000 description 141
- 102000004196 processed proteins & peptides Human genes 0.000 description 60
- 239000012528 membrane Substances 0.000 description 46
- 235000001014 amino acid Nutrition 0.000 description 38
- 229940024606 amino acid Drugs 0.000 description 38
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 210000002767 hepatic artery Anatomy 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000012800 visualization Methods 0.000 description 10
- 208000005189 Embolism Diseases 0.000 description 9
- 210000001367 artery Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000003240 portal vein Anatomy 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 229960004793 sucrose Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- -1 alkalis Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229960004647 iopamidol Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 108010067520 RADA16-I Proteins 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 238000002583 angiography Methods 0.000 description 5
- 230000008236 biological pathway Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000008241 heterogeneous mixture Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003073 embolic effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002254 renal artery Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000013161 embolization procedure Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000009878 intermolecular interaction Effects 0.000 description 3
- 229940126586 small molecule drug Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920001651 Cyanoacrylate Polymers 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 2
- 241000750004 Nestor meridionalis Species 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 101800005149 Peptide B Proteins 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 229940039231 contrast media Drugs 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 108010091748 peptide A Proteins 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 101150036383 rad16 gene Proteins 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 210000002563 splenic artery Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- KHQDWCKZXLWDNM-KPKJPENVSA-N (e)-2-ethyl-4-(2,2,3-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol Chemical compound CC\C(CO)=C/CC1CC=C(C)C1(C)C KHQDWCKZXLWDNM-KPKJPENVSA-N 0.000 description 1
- PXGILEVFPBXLEB-UHFFFAOYSA-N 1,2-dimethyl-3-propan-2-ylazulene Chemical compound C1=CC=CC=C2C(C(C)C)=C(C)C(C)=C21 PXGILEVFPBXLEB-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RIWRBSMFKVOJMN-UHFFFAOYSA-N 2-methyl-1-phenylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=CC=C1 RIWRBSMFKVOJMN-UHFFFAOYSA-N 0.000 description 1
- MLLAPOCBLWUFAP-UHFFFAOYSA-N 3-Methylbutyl benzoate Chemical compound CC(C)CCOC(=O)C1=CC=CC=C1 MLLAPOCBLWUFAP-UHFFFAOYSA-N 0.000 description 1
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100031695 DnaJ homolog subfamily C member 2 Human genes 0.000 description 1
- 108010061519 EAK16 peptide Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101710185584 Extracellular matrix protein A Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PMGCQNGBLMMXEW-UHFFFAOYSA-N Isoamyl salicylate Chemical compound CC(C)CCOC(=O)C1=CC=CC=C1O PMGCQNGBLMMXEW-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101710112814 Zuotin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000037872 brain arteriovenous malformation Diseases 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
- 229950010048 enbucrilate Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 229940031124 ethanolamine oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- BOPPSUHPZARXTH-UHFFFAOYSA-N ocean propanal Chemical compound O=CC(C)CC1=CC=C2OCOC2=C1 BOPPSUHPZARXTH-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- FVEFRICMTUKAML-UHFFFAOYSA-M sodium tetradecyl sulfate Chemical compound [Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O FVEFRICMTUKAML-UHFFFAOYSA-M 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 229940010746 sotradecol Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/12186—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/504—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of blood vessels, e.g. by angiography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
- A61B17/12113—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/007—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Radiology & Medical Imaging (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Dentistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本願は、ASCII形式で電子的に提出された配列表を含み、この配列表は、その全体が本明細書中に援用される。上記ASCIIの写しは、2013年11月14日に作製され、T2071−7000WO_SL.txtという名前であり、サイズが23,527バイトである。
本開示は、医療、研究、および産業用途において使用され得る肉眼で見える膜(macroscopic membrane)に関する。より具体的には、本開示は、血管塞栓システムおよび塞栓形成手順において使用され得る膜、ヒドロゲル、組成物および溶液に関する。血管塞栓システムは、脈管、静脈、門脈、動脈、および、血液および他の流体(例えば、リンパ液)を輸送し得る管を含む生物学的経路もしくはチャネルを少なくとも部分的に遮断するアプローチを提供し得る。
被験体における生物学的脈管を遮断するための方法が提供される。上記方法は、生物学的脈管にカテーテルを導入する工程および上記カテーテルの末端を、少なくとも部分的閉塞が所望される生物学的脈管の標的領域に配置する工程を包含する。上記方法は、上記カテーテルを介して、生理学的条件下でヒドロゲルを形成して上記生物学的脈管の少なくとも部分的遮断を可能にするために有効な量で、および有効な濃度で、疎水性アミノ酸と親水性アミノ酸とが交互になっている少なくとも12個のアミノ酸を含む両親媒性ペプチドを含む溶液を投与する工程をさらに包含する。上記方法は、上記カテーテルを、少なくとも部分的閉塞を適所に有する上記生物学的脈管から取り除く工程をさらに包含する。
塞栓形成は、1つ以上の生物学的経路もしくはチャネルにおいて遮断、滞留(lodging)、閉塞、もしくは塞栓を作る手順である。上記生物学的経路もしくはチャネルは、脈管、静脈、門脈、動脈、および、血液および他の流体(例えば、リンパ液)を輸送し得る管を含み得る。塞栓形成は、被験体の身体(ヒトの身体が挙げられる)の種々の器官に影響を及ぼす種々様々な状態を処置するために使用される。1つ以上の上記脈管は、所望の標的への血液循環を意図的に防止するもしくは低減するために標的化され得る。上記塞栓形成手順は、腫瘍もしくはそれらの血液供給(灌流)からの他の病理過程を取り除くために、このような遮断、滞留もしくは閉塞を意図的に作るために使用され得る。塞栓形成は、生物学的脈管における障害、奇形、もしくは先天的病気を処置するために使用され得る。例えば、塞栓形成は、動脈管開存症(PDA)を処置するために使用され得る。上記塞栓形成処置は、主要大動脈肺動脈側副動脈(MAPCA)、再発性の喀血(recurrent hemotysis)、動静脈奇形、脳動脈瘤、消化管出血、鼻出血、分娩後出血、術中出血、および子宮類線維腫を処置するために使用され得る。
3%(重量/体積(w/v)) PuraMatrixTM溶液、Ac−RADARADARADARADA−NH2(Ac−Arg−Ala−Asp−Ala−Arg−Ala−Asp−Ala−Arg−Ala−Asp−Ala−Arg−Ala−Asp−Ala−NH2)(配列番号58)を水中に含むペプチド溶液を使用して、ラットで試験を行った。18ゲージニードルを使用して、1ミリリットル(mL)をラットの門脈に注射した。
2.5% PuraMatrixTM溶液、Ac−RADARADARADARADA−NH2(Ac−Arg−Ala−Asp−Ala−Arg−Ala−Asp−Ala−Arg−Ala−Asp−Ala−Arg−Ala−Asp−Ala−NH2)(配列番号58)を水中に含むペプチド溶液を使用して、2匹のビーグル犬で試験を行った。これらの試験を行ったところ、上記2.5% ペプチド溶液を使用するビーグル犬の肝動脈塞栓の有効性および肝細胞壊死が確認された。上記ペプチド溶液は、濃度612.4mg/mLのイオパミドールを含んだ。イオパミドールは、非イオン性放射線不透過性造影剤である。
PuraMatrixTM、Ac−RADARADARADARADA−NH2(Ac−Arg−Ala−Asp−Ala−Arg−Ala−Asp−Ala−Arg−Ala−Asp−Ala−Arg−Ala−Asp−Ala−NH2)(配列番号58)を水中に含むペプチド溶液を、血管造影法、全般的剖検評価(gross necropsy assessment)、および組織病理学評価を通じて、ブタモデルにおいて塞栓系製剤として使用した。1頭の雌性ヨークシャー交配種ブタ(Yorkshire cross swine)を試験した。試験時の上記ブタの体重は、46.5kgであった。飼料および水を、標準的な作業手順に従って提供した。上記研究の管理もしくは結果に干渉すると予測される飼料もしくは水の汚染は無かった。上記ブタを、試験施設承認の動物供給業者から獲得した。上記ブタには到着時身体検査を行い、順応期間後、再び検査した。上記ブタを、上記手順の前に最低12時間絶食させた。上記動物を鎮静させ、テラゾール(2〜10mg/kg)およびキシラジン(0.5〜5.0mg/kg)の筋肉内もしくは皮下注射によって麻酔した。プロポフォール(効くまで)を鎮静の補助に与えた。気管内チューブを使用して適切な換気を確保し、上記動物を、吸入用イソフルラン(inhalant isofluorante)(0.1〜5.0%)で、全身麻酔下で維持した。ヘパリン(50〜300単位/kg, IV)を、上記手順の間中、投与した。
Claims (53)
- 被験体において生物学的脈管を遮断するための方法であって、該方法は、
カテーテルを生物学的脈管に導入する工程;
該カテーテルの末端を、少なくとも部分的閉塞が所望される該生物学的脈管の標的領域に配置する工程;
該カテーテルを介して、生理学的条件下でヒドロゲルを形成して、該生物学的脈管の少なくとも部分的遮断を可能にするために有効な量で、および有効な濃度で、疎水性アミノ酸と親水性アミノ酸とが交互になっている少なくとも12個のアミノ酸を含む両親媒性ペプチドを含む溶液を投与する工程;
該カテーテルを、該少なくとも部分的閉塞を適所に有する該生物学的脈管から取り除く工程;
を包含する、方法。 - 前記ペプチド溶液は、造影剤を含む、請求項1に記載の方法。
- 前記生物学的脈管の少なくとも一部を含む局部を可視化する工程をさらに包含する、請求項2に記載の方法。
- 前記生物学的脈管の少なくとも一部を含む前記局部を可視化する工程は、以下:
該生物学的脈管の前記標的領域を同定する工程;
該カテーテルを導入する工程;
該カテーテルの前記末端を該標的領域に配置する工程;
前記溶液を投与する工程;
該カテーテルを取り除く工程;および
該カテーテルを取り除いた後に、該生物学的脈管を可視化する工程
のうちの少なくとも1つの間に該局部を可視化する工程を包含する、請求項3に記載の方法。 - 前記局部を可視化する工程は、X線撮影法を使用して画像化する工程を包含する、請求項4に記載の方法。
- 前記局部を可視化する工程は、前記生物学的脈管への前記溶液の選択的投与を提供する、請求項3に記載の方法。
- 前記投与の約2週間後の期間に前記局部を可視化する工程をさらに包含する、請求項3に記載の方法。
- 前記有効な量および前記有効な濃度のうちの少なくとも一方は、前記生物学的脈管の標的領域の直径に一部基づく、請求項1に記載の方法。
- 前記有効な量および前記有効な濃度のうちの少なくとも一方は、前記生物学的脈管中の血液の流速に一部基づく、請求項1に記載の方法。
- 前記有効な量および前記有効な濃度のうちの少なくとも一方は、前記被験体の赤血球の平均直径より小さな平均孔サイズを有する前記ヒドロゲルのナノ線維を提供する工程に一部基づく、請求項1に記載の方法。
- 前記生物学的脈管の少なくとも部分的遮断を可能にするために有効な前記濃度は、約0.1重量/体積(w/v)%〜約3w/v% ペプチドの範囲の濃度を含む、請求項1に記載の方法。
- 前記生物学的脈管の少なくとも部分的遮断を可能にするために有効な前記量は、約0.1mL〜約5mLの範囲の体積を含む、請求項1に記載の方法。
- 前記少なくとも部分的遮断の周りの前記領域をモニターして、前記少なくとも部分的閉塞の有効性を決定する工程をさらに包含する、請求項1に記載の方法。
- 形成される前記遮断は、生物学的脈管における障害、奇形、もしくは先天的病気の処置において使用される、請求項1に記載の方法。
- 形成される前記遮断は、動脈管開存症(PDA)および主要大動脈肺動脈側副動脈(MAPCA)のうちの一方の処置において使用される、請求項14に記載の方法。
- 形成される前記遮断は、再発性の喀血、動静脈奇形、脳動脈瘤、消化管出血、鼻出血、分娩後出血、術中出血、および子宮類線維腫からなる群より選択される障害、奇形、もしくは先天的病気の処置において使用される、請求項14に記載の方法。
- 形成される前記遮断は、がん細胞の低減において使用される、請求項1に記載の方法。
- 前記ペプチド溶液は、細胞を実質的に含まない、請求項1に記載の方法。
- 前記ペプチド溶液は、薬物を実質的に含まない、請求項1に記載の方法。
- 前記被験体は、哺乳動物である、請求項1に記載の方法。
- 前記被験体は、ヒトである、請求項20に記載の方法。
- 前記溶液を投与する工程は、該溶液を単一用量で投与する工程を包含する、請求項1に記載の方法。
- 前記溶液を投与する工程は、該溶液を少なくとも2用量で投与する工程を包含する、請求項1に記載の方法。
- 前記ペプチドは、RADARADARADARADA(配列番号7)、IEIKIEIKIEIKI(配列番号8)、およびIEIKIEIKIEIKIEIKI(配列番号9)のうちの1つのアミノ酸配列を有する、請求項1に記載の方法。
- 前記被験体を評価して、生物学的脈管を遮断する工程および前記ペプチド溶液を調製する工程についての必要性を決定する工程をさらに包含する、請求項1に記載の方法。
- 前記ペプチド溶液を調製する工程は、造影剤を、ペプチドを含む予備溶液に添加する工程を包含する、請求項25に記載の方法。
- 前記溶液は、前記生物学的脈管の完全な遮断を可能にするために投与される、請求項1に記載の方法。
- 前記カテーテルを導入する前に、前記生物学的脈管にガイドワイヤを導入する工程をさらに包含する、請求項1に記載の方法。
- 被験体において生物学的脈管を遮断するためのキットであって、該キットは、
生理学的条件下でヒドロゲルを形成して、該生物学的脈管の少なくとも部分的遮断を可能にするために有効な量で、および有効な濃度で、疎水性アミノ酸と親水性アミノ酸とが交互になっている少なくとも12個のアミノ酸を含む両親媒性ペプチドを含む溶液;ならびに
該被験体における該生物学的脈管への該溶液の投与のための指示、
を含む、キット。 - 前記溶液を前記被験体の前記生物学的脈管へと導入するためのカテーテルをさらに含む、請求項29に記載のキット。
- 前記溶液を投与する工程を可視化するために適した量で造影剤を該溶液に添加するための指示をさらに含む、請求項29に記載のキット。
- 造影剤およびスクロース溶液のうちの少なくとも一方をさらに含む、請求項31に記載のキット。
- 前記溶液の有効な濃度を前記被験体において前記生物学的脈管に投与するために、該溶液を希釈するための指示をさらに含む、請求項29に記載のキット。
- 標的領域にある前記生物学的脈管の直径に基づいて、前記被験体における該生物学的脈管への前記溶液の前記有効な濃度を決定するための指示をさらに含む、請求項33に記載のキット。
- 被験体において生物学的脈管を遮断するのを促進するための方法であって、該方法は、
生理学的条件下でヒドロゲルを形成して、該生物学的脈管の少なくとも部分的遮断を可能にするために有効な量で、および有効な濃度で、疎水性アミノ酸と親水性アミノ酸とが交互になっている少なくとも12個のアミノ酸を含む両親媒性ペプチドを含む溶液を提供する工程;および
該生物学的脈管に配置されたカテーテルへの該溶液の導入を介して、該溶液を該生物学的脈管の標的領域に投与するための指示を提供する工程、
を包含する、方法。 - 造影剤を前記溶液に添加するための指示を提供する工程をさらに包含する、請求項35に記載の方法。
- 前記生物学的脈管の少なくとも一部を含む局部を可視化するための指示を提供する工程をさらに包含する、請求項36に記載の方法。
- 前記生物学的脈管の少なくとも一部を含む局部を可視化するための指示を提供する工程は、以下:
該生物学的脈管の標的領域を同定する工程;
カテーテルを導入する工程;
該標的領域に該カテーテルの末端を配置する工程;
前記溶液を投与する工程;
該カテーテルを、前記少なくとも部分的遮断を適所に有する該生物学的脈管から取り除く工程;および
該カテーテルを取り除いた後に、該生物学的脈管を可視化する工程、
のうちの少なくとも1つの間に該局部を可視化するための指示を提供する工程を包含する、請求項37に記載の方法。 - 前記局部を可視化するための指示を提供する工程は、X線撮影法を使用して画像化する工程を包含する、請求項38に記載の方法。
- 前記投与の約2週間後の期間に、前記局部を可視化するための指示を提供する工程をさらに包含する、請求項37に記載の方法。
- 前記有効な量および前記有効な濃度のうちの少なくとも一方を、前記生物学的脈管の前記標的領域の直径に一部基づいて調製するための指示を提供する工程を包含する、請求項35に記載の方法。
- 前記有効な量および前記有効な濃度のうちの少なくとも一方は、前記生物学的脈管中の血液の流速に一部基づく、請求項35に記載の方法。
- 前記有効な量および前記有効な濃度のうちの少なくとも一方は、前記被験体の赤血球の平均直径より小さい平均孔サイズを有するヒドロゲルを提供することに一部基づく、請求項35に記載の方法。
- 前記生物学的脈管の少なくとも部分的遮断を可能にするために有効な前記濃度は、約0.1重量%〜約3重量% ペプチドの範囲の濃度を含む、請求項35に記載の方法。
- 前記生物学的脈管の少なくとも部分的遮断を可能にするために有効な前記量は、約0.1mL〜約5mLの範囲の体積を含む、請求項35に記載の方法。
- 前記少なくとも部分的遮断の周りの前記局部をモニターして、細胞壊死を決定するための指示を提供する工程をさらに包含する、請求項35に記載の方法。
- 形成される前記遮断は、生物学的脈管における障害、奇形、もしくは先天的病気の処置において使用される、請求項35に記載の方法。
- 形成される前記遮断は、がん細胞の低減において使用される、請求項35に記載の方法。
- 前記ペプチド溶液は、細胞を実質的に含まない、請求項35に記載の方法。
- 前記ペプチド溶液は、薬物を実質的に含まない、請求項35に記載の方法。
- 前記被験体は、哺乳動物である、請求項35に記載の方法。
- 前記被験体は、ヒトである、請求項51に記載の方法。
- 前記ペプチドは、RADARADARADARADA(配列番号7)、IEIKIEIKIEIKI(配列番号8)、およびIEIKIEIKIEIKIEIKI(配列番号9)のうちの1つのアミノ酸配列を有する、請求項35に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261726250P | 2012-11-14 | 2012-11-14 | |
US61/726,250 | 2012-11-14 | ||
PCT/IB2013/060145 WO2014076660A1 (en) | 2012-11-14 | 2013-11-14 | Vascular embolic system |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018032093A Division JP2018086425A (ja) | 2012-11-14 | 2018-02-26 | 血管塞栓システム |
JP2019091205A Division JP2019122875A (ja) | 2012-11-14 | 2019-05-14 | 血管塞栓システム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016501066A true JP2016501066A (ja) | 2016-01-18 |
JP2016501066A5 JP2016501066A5 (ja) | 2019-02-14 |
Family
ID=49725176
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015542401A Pending JP2016501066A (ja) | 2012-11-14 | 2013-11-14 | 血管塞栓システム |
JP2018032093A Pending JP2018086425A (ja) | 2012-11-14 | 2018-02-26 | 血管塞栓システム |
JP2019091205A Pending JP2019122875A (ja) | 2012-11-14 | 2019-05-14 | 血管塞栓システム |
JP2021114234A Pending JP2021164739A (ja) | 2012-11-14 | 2021-07-09 | 血管塞栓システム |
JP2023103314A Pending JP2023115128A (ja) | 2012-11-14 | 2023-06-23 | 血管塞栓システム |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018032093A Pending JP2018086425A (ja) | 2012-11-14 | 2018-02-26 | 血管塞栓システム |
JP2019091205A Pending JP2019122875A (ja) | 2012-11-14 | 2019-05-14 | 血管塞栓システム |
JP2021114234A Pending JP2021164739A (ja) | 2012-11-14 | 2021-07-09 | 血管塞栓システム |
JP2023103314A Pending JP2023115128A (ja) | 2012-11-14 | 2023-06-23 | 血管塞栓システム |
Country Status (5)
Country | Link |
---|---|
US (2) | US20160287744A1 (ja) |
EP (1) | EP2919826A1 (ja) |
JP (5) | JP2016501066A (ja) |
HK (1) | HK1215200A1 (ja) |
WO (1) | WO2014076660A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019508181A (ja) * | 2016-03-18 | 2019-03-28 | 株式会社スリー・ディー・マトリックス | 脳脊髄液の漏出の閉鎖 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010041636A1 (ja) | 2008-10-06 | 2010-04-15 | 株式会社スリー・ディー・マトリックス | 組織閉塞剤 |
EP3466964A1 (en) | 2012-07-06 | 2019-04-10 | 3-D Matrix Ltd. | Fill-finish process for peptide solutions |
WO2015138514A1 (en) * | 2014-03-10 | 2015-09-17 | 3-D Matrix, Ltd. | Self-assembling peptide compositions |
WO2015136370A2 (en) | 2014-03-10 | 2015-09-17 | 3-D Matrix, Ltd. | Sterilization and filtration of peptide compositions |
US10245299B2 (en) | 2014-03-10 | 2019-04-02 | 3-D Matrix, Ltd. | Autoassembling peptides for the treatment of pulmonary bulla |
ES2843324T3 (es) * | 2014-11-18 | 2021-07-16 | Maximum Fidelity Surgical Simulations Llc | Reconstitución de la circulación post mortem |
US10814038B2 (en) | 2016-01-06 | 2020-10-27 | 3-D Matrix, Ltd. | Combination compositions |
AU2017232540A1 (en) * | 2016-03-18 | 2018-09-27 | 3-D Matrix, Ltd. | Preventing biological tissue adhesion |
US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
WO2019094959A1 (en) | 2017-11-13 | 2019-05-16 | Fernandez Joss | Reconstitution of post mortem circulation, specialized methods and procedures |
US11716989B2 (en) | 2019-04-16 | 2023-08-08 | Maximum Fidelity Surgical Simulations, LLC | Cadaver preservation systems and methods |
WO2020232402A1 (en) | 2019-05-15 | 2020-11-19 | Maximum Fidelity Surgical Simulations, LLC | Cadaverous heart model |
CN115397454A (zh) | 2020-03-31 | 2022-11-25 | 立美基股份有限公司 | 通过辐照对自组装肽进行灭菌 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010041636A1 (ja) * | 2008-10-06 | 2010-04-15 | 株式会社スリー・ディー・マトリックス | 組織閉塞剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3031466B1 (en) * | 2004-07-06 | 2018-11-28 | 3D Matrix, Inc. | Purified amphiphilic peptide compositions and uses thereof |
MX2007004261A (es) * | 2004-10-12 | 2007-06-18 | Fmc Biopolymer As | Sistemas de alginato auto-gelificantes y usos de los mismos. |
US9987221B2 (en) * | 2007-08-23 | 2018-06-05 | Boston Scientific Scimed, Inc. | Injectable hydrogel compositions |
JP2012100680A (ja) * | 2009-03-04 | 2012-05-31 | Terumo Corp | 血管内用処置材 |
US20120123355A1 (en) * | 2009-07-30 | 2012-05-17 | Cook Medical Technologied | Erodible embolization material |
US20110117195A1 (en) * | 2009-11-18 | 2011-05-19 | National Cheng Kung University | Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers |
CA2831414C (en) * | 2011-03-30 | 2016-03-22 | Toray Industries, Inc. | Biodegradable particle, vascular embolization material and method for producing biodegradable particles |
-
2013
- 2013-11-14 US US14/442,677 patent/US20160287744A1/en not_active Abandoned
- 2013-11-14 JP JP2015542401A patent/JP2016501066A/ja active Pending
- 2013-11-14 WO PCT/IB2013/060145 patent/WO2014076660A1/en active Application Filing
- 2013-11-14 EP EP13802115.9A patent/EP2919826A1/en active Pending
-
2016
- 2016-03-17 HK HK16103152.0A patent/HK1215200A1/zh unknown
-
2018
- 2018-02-26 JP JP2018032093A patent/JP2018086425A/ja active Pending
-
2019
- 2019-05-14 JP JP2019091205A patent/JP2019122875A/ja active Pending
-
2021
- 2021-07-09 JP JP2021114234A patent/JP2021164739A/ja active Pending
- 2021-11-24 US US17/535,470 patent/US20220168462A1/en active Pending
-
2023
- 2023-06-23 JP JP2023103314A patent/JP2023115128A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010041636A1 (ja) * | 2008-10-06 | 2010-04-15 | 株式会社スリー・ディー・マトリックス | 組織閉塞剤 |
Non-Patent Citations (1)
Title |
---|
消化器外科 NURSING, vol. 13, no. 10, JPN6017040511, 2008, pages 39 - 42, ISSN: 0004087689 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019508181A (ja) * | 2016-03-18 | 2019-03-28 | 株式会社スリー・ディー・マトリックス | 脳脊髄液の漏出の閉鎖 |
Also Published As
Publication number | Publication date |
---|---|
JP2018086425A (ja) | 2018-06-07 |
JP2019122875A (ja) | 2019-07-25 |
US20160287744A1 (en) | 2016-10-06 |
EP2919826A1 (en) | 2015-09-23 |
JP2023115128A (ja) | 2023-08-18 |
JP2021164739A (ja) | 2021-10-14 |
HK1215200A1 (zh) | 2016-08-19 |
US20220168462A1 (en) | 2022-06-02 |
WO2014076660A1 (en) | 2014-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220168462A1 (en) | Vascular embolic system | |
AU2014229273B2 (en) | Materials for gastrointestinal obstruction prevention | |
JP6545727B2 (ja) | 肺大気胞を治療するための自発組織化ペプチド | |
US20160030628A1 (en) | Treatment for bile leakage | |
JP2020011125A (ja) | 肺の漏出を治療するための自発組織化ペプチド | |
JP2017510400A (ja) | 気管支閉鎖剤としての自己組織化ペプチド | |
US20200078489A1 (en) | Pancreatic fistula occlusion | |
US20230241294A1 (en) | Preventing biological tissue adhesion | |
US20210023257A1 (en) | Cerebrospinal fluid leakage occlusion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161111 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171026 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180618 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180823 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181025 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20181225 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190514 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190701 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190802 |